First in a series of two columns on creating a plan to treat depression. In my last column on preventing and identifying depression, I promised to create a guide to help you come up with a perfectly individualized plan to treat your depression. Just as no…
Sangamo Therapeutics and Pfizer will work together on gene therapies they hope will overcome mutations that cause ALS and frontotemporal lobar degeneration. Gene therapy works by delivering a healthy copy of a malfunctioning gene to a patient. The therapy that Sangamo is developing replaces a faulty C9orf72 gene. It consists…
This illustrated video from Stichting ALS Nederland briefly explains the neurodegenerative disease, amyotrophic lateral sclerosis (ALS). MORE: Could exercise help ALS patients with swallowing? It explains the progression of the disease and how it affects patients. ALS causes the brain and spinal cord to stop transmitting signals to…
Cell stress, such as a viral infection, may trigger the production of faulty proteins from the C9orf72 gene, a leading contributor of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), say researchers at the University of Michigan. Their study, “RAN translation at C9orf72-associated repeat expansions is selectively enhanced…
Real Madrid and Portugal international soccer player, Cristiano Ronaldo, proves his worth off the pitch as well as on it as he welcomed a former soccer player who has been diagnosed with amyotrophic lateral sclerosis (ALS) to watch a game at the Bernabeu stadium in Madrid (in Ronaldo’s private box, no…
Rural residents with high school diplomas are at lower risk of developing dementia and cognitive impairment than those with less education, a study indicates. The study has healthcare policy implications, including providing more care to those in rural areas with dementia and cognition-related disorders such as Alzheimer’s and ALS. Researchers…
Throughout 2017, ALS News Today brought you daily coverage of amyotrophic lateral sclerosis (ALS)-related advocacy events, clinical studies, and the latest research updates. We have compiled a top 10 list of the most-read ALS news stories of that year, with a brief description of what made them interesting and…
With the holiday season in full swing, it’s the perfect opportunity to take a look back at 2017. It’s been a year full of ups and downs, and while there were definitely quite a few low moments, there were certainly quite a few highs. To celebrate the year that was,…
Gene editing may be a viable tool to slow disease-causing processes in amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, a mouse study indicates. Published in the journal Science Advances, the study demonstrated that the method delayed disease…
Q Therapeutics of the United States and REPROCELL of Japan are teaming up to develop stem cell-based therapies for central nervous system diseases such as ALS and transverse myelitis, or TM. The collaboration will meld Q Therapeutics’ expertise in nerve cell therapy with REPROCELL’s expertise in stem cell treatments.
Get regular updates to your inbox.